Startseite

Analyse

Fundierte Analysen zu Pharmamärkten, Lieferketten, Technologie und Regulierung

#Korea ×

Analyse
27. Sept. 2026•1 Min. Lesezeit
Mounjaro Leads Surge in Korean Obesity Drug Market, Wegovy Falls to 5th
Mounjaro drove over 30% growth in Korea's obesity treatment market in two months, while Wegovy sales fell for two consecutive months, dropping to fifth place.
Analyse
24. Sept. 2026•1 Min. Lesezeit
Oseltamivir Suspension Powder Faces Supply Shortage Amid Rapid Flu Spread in Korea
Pharmacies report stockouts of pediatric oseltamivir suspension powder as influenza cases surge; some manufacturers still hold inventory, but supply pressure is rising.
Analyse
22. Sept. 2026•1 Min. Lesezeit
Jongkundang's Zitec GI drug pushes for reimbursement as insurer weighs clinical and industrial value
Jongkundang is working to secure reimbursement for its domestically developed GI medication Zitec, with the National Health Insurance Service evaluating its clinical usefulness, industrial value, alternative drug pricing, and fiscal impact.
Analyse
20. Sept. 2026•1 Min. Lesezeit
Korea Pfizer partners with Il Dong Pharma to distribute Nutex migraine oral tablet
Korea Pfizer and Il Dong Pharmaceutical have signed a distribution and joint promotion agreement for the migraine drug Nutex oral disintegrating tablet, leveraging Il Dong's CNS sales expertise to accelerate market entry.
Analyse
19. Sept. 2026•1 Min. Lesezeit
Korean Pharmacy Names Shift Toward Numeric and Scale‑Based Branding
Analysis of 25,862 operating pharmacies shows a move from friendly names like 'Health' to business‑focused names such as '365' and 'Mega'.
Analyse
19. Sept. 2026•1 Min. Lesezeit
Samnam Pharmaceutical’s Magmil Leads August Pharmacy Restock Alerts in Korea
Magmil tablets from Samnam Pharmaceutical recorded the highest number of out‑of‑stock restock requests in August, with 26,673 alerts, according to BRPConnect data.
Analyse
14. Sept. 2026•1 Min. Lesezeit
Hanmi and Dongkook Lead Ibuprofen Cold Medicine Market; Chong Kun Dang and Dong‑A Join Competition This Fall
After the 2025 OTC standard change, Hanmi and Dongkook launched ibuprofen‑combination cold medicines last winter, and this fall Chong Kun Dang and Dong‑A are entering, expanding market competition.
Analyse
13. Sept. 2026•1 Min. Lesezeit
South Korea Bio‑Health Exports Hit $1.41 B in August, +22.3% YoY
Korea’s bio‑health industry posted its highest August export ever, $1.41 billion, a 22.3% increase from last year, while cumulative 2026 exports reached $12.11 billion.
1
Analyse
13. Sept. 2026•1 Min. Lesezeit
CGRP-Targeted Migraine Drugs Expand in Korea with New Formulations
CGRP-based migraine therapies are rapidly entering the Korean market, offering injectable and oral options that diversify treatment beyond traditional CNS‑active drugs.
Analyse
8. Sept. 2026•1 Min. Lesezeit
Dongkook Pharmaceutical Launches TECA Plus Formula Facial Repair Cream Light
Dongkook Pharmaceutical’s dermal repair brand Madecaphamacia introduced the TECA Plus Formula Facial Repair Cream Light, featuring enhanced moisture, absorption, and added PDRN, available in ~6,000 Korean pharmacies.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Daewon Pharmaceutical Continues Production and Sale of Cough Expectorant KoDaewon
Daewon Pharmaceutical will keep producing and supplying the cough expectorant Ko Daewon Jeong, aiming to maintain patient convenience and avoid prescribing confusion.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Metropolitan pharmacy franchise fees diverge from traditional sales‑multiple formula
A 20‑pyeong pharmacy with 21 MKR monthly sales was priced at 750 MKR, while one with 30 MKR sales fetched 600 MKR, showing a shift from the usual 25‑30× sales rule.